Paula Ragan - 12 Feb 2025 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: President and CEO, Director
Issuer ticker: XFOR
Reported as of: 12 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Feb 2025, 16:08:38 UTC
Prior SEC filing: 27 Jan 2025
Next SEC filing: 27 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Adam S. Mostafa, attorney-in-fact

Key filing fact

Paula Ragan filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 14 Feb 2025.

Key facts

This page summarizes Paula Ragan's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Feb 2025, 16:08.

Change

Previous filing in this sequence was filed on 27 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Award

Transaction value: $0
Shares: +2,250,000
Change %: +207%
Price: $0.000000
Shares after: 3,337,386
Date: 12 Feb 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.